scholarly journals Higher Expression of Epidermal Growth Factor Receptor Is Associated with Extracellular Matrix Metalloprotease Inducer in Colorectal Adenocarcinoma: Tissue Microarray Analysis of Immunostaining Score with Clinicopathological Parameters

2006 ◽  
Vol 22 (5-6) ◽  
pp. 309-316 ◽  
Author(s):  
Jong-Shiaw Jin ◽  
Chi-Ying Wu ◽  
Yeh-Feng Lin ◽  
Jia-Yi Wang ◽  
Cheng-Ping Yu ◽  
...  
Keyword(s):  
Colorectal Adenocarcinoma ◽  
Growth Factor Receptor ◽  
Clinicopathological Parameters ◽  
Colorectal Cancers ◽  
Matrix Metalloprotease ◽  
Egfr Expression ◽  
Poorly Differentiated ◽  
Epidermal Growth ◽  
Well Differentiated ◽  
Colorectal Adenocarcinomas

Aim: Extracellular matrix metalloprotease inducer (EMMPRIN) expression was demonstrated in several cancers, but its expression profile in colorectal cancers remains unclear. Epidermal growth factor receptor (EGFR) was reported to regulate EMMPRIN expression in human epithelial cancers. Our purpose was to determine EMMPRIN expression and its relationship with EGFR in colorectal cancers.Methods: Immunohistochemical analysis of EMMPRIN and EGFR was performed in tissue microarray slides of 90 surgical specimens including 32 well differentiated, 35 moderately differentiated, and 23 poorly differentiated colorectal adenocarcinomas.Results: All colorectal adenocarcinomas showed significant immunohistochemical expression of EMMPRIN. The EMMPRIN scores in poorly differentiated (303 ± 21) and moderately differentiated (326 ± 17) colorectal adenocarcinoma were significantly higher than in well differentiated (166 ± 20) colorectal adenocarcinoma. EGFR expression was mainly on the cell surface of tumor cells and the immunostaining scores of EGFR were significantly associated with the advanced clinical T and N stages. A significantly positive relationship between EMMPRIN and EGFR immunostaining scores was also noted.Conclusions: Increased expression of EMMPRIN and EGFR in colorectal adenocarcinomas is associated with clinicopathological parameters of advanced colorectal adenocarcinoma stages.In addition, the data from this study support the notion that EGFR expression may up-regulate EMMPRIN expression.

scholarly journals EGFR and HER2neu Expression in Gall Bladder Carcinoma and Its Association with Clinicopathological Parameters - An Institutional Experience from North India

2021 ◽  
Vol 6 (1) ◽  
pp. 57-65
Author(s):  
Inara Abeer ◽  
Sabina Khan ◽  
Mohd. Jaseem Hasan ◽  
Musharraf Hussain
Keyword(s):  
Gall Bladder ◽  
Bladder Carcinoma ◽  
North India ◽  
Clinicopathological Parameters ◽  
Advanced Stage ◽  
Gall Bladder Carcinoma ◽  
Egfr Expression ◽  
Poorly Differentiated ◽  
Well Differentiated ◽  
Biliary Tract Malignancy

Objective: Gallbladder cancer (GBC) is the most common biliary tract malignancy found worldwide with very high incidence in North India especially Delhi region. It is characterized by poor prognosis and ineffective treatment especially in advanced stage. The aim of this study was to evaluate EGFR and HER2/neu immunoexpression in cancer patients and to correlate it with the clinicopathological parameters so as to identify GBC patients who can benefit from targeted therapy.Methods: Present study was conducted in the Department of Pathology, Hamdard Institute of Medical Sciences & Research, New Delhi. A total of 40 cases of Gallbladder carcinoma (GBC) were evaluated for Immunohistochemical expression of EGFR and HER2/neu. Clinicopathological parameters of GBC were studied and correlated with immunoexpression of EGFR and HER2 /neu. Result: The mean age of the GBC patients was 55.9 years with 90% being females. On histopathology, 34(85%) cases were conventional adenocarcinoma. The EGFR expression was positive in 29/40 cases (72.5%). It was significantly more positive in poorly differentiated grade and advanced stages of gall bladder carcinoma (P<0.05). The expression of HER2/neu was positive in 13/40 cases (32.5%). It was significantly more positive in well differentiated gall bladder carcinoma (P<0.05). Immunoexpression of EGFR was inversely related with HER2/neu expression and this association was statistically significant.Conclusion: Among GBC patients, EGFR expression and HER2/neu expression was 72.5% and 32.5%, respectively. Significant EGFR expression was seen in poorly differentiated and advanced stage cancers while significant HER2/neu expression was seen in well differentiated gall bladder carcinomas. To conclude, these two markers HER2/neu and EGFR can be used as predictive and prognostic markers respectively, with rationale to further explore the use of anti-HER2 and anti- EGFR therapy in gall bladder cancer.

Immunoexpression of Epidermal Growth Factor Receptor (EGFR) in Malignant Surface Epithelial Tumours of Ovary

2019 ◽  
Vol 31 (3) ◽  
pp. 219-225
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Clear Cell ◽  
Growth Factor Receptor ◽  
Ovarian Cancers ◽  
Ovarian Tumours ◽  
Epithelial Tumours ◽  
Poorly Differentiated ◽  
Epidermal Growth ◽  
Epithelial Ovarian Tumours ◽  
Well Differentiated

Ovarian cancer is the deadliest gynaecological cancer and approximately 70% are diagnosed in an advanced stage with 5 years survival rate of only 35%. The aim of this study was to find out the distribution of epidermal growth factor receptor (EGFR) immunoexpression in different histological types and grades of malignant surface epithelial tumours of ovary. A total 54 cases of malignant surface epithelial tumours of ovary from North Okkalapa General and Teaching Hospital and Thingangyun Sanpya General Hospital from August 2015 to September 2016 were included. This study included 30 cases (56%) of serous tumour, 18 cases (33%) mucinous tumour, 5 cases (9%) clear cell tumour and one case (2%) of malignant Brenner tumour. Of the 54 cases, 11 cases (20%) were well differentiated, 33 cases (61%) moderately differentiated and 10 cases (19%) poorly differentiated tumours. Different histological types and grades of malignant surface epithelial ovarian tumours were determined for EGFR immunoexpression by peroxidase antiperoxidase method. Out of 54 cases, 31 cases (57.4%) were found to be positive for EGFR immunoexpression and 23 cases (42.6%) showed negative immunoexpression. Among 31 positive cases of EGFR, 54.8% were serous, 32.3% mucinous, 9.7% clear cell and 3.2% were malignant Brenner tumour. The highest EGFR immunoexpression was found in malignant serous, tumour (54.8%). Regarding the histological grades of the 31 positive cases, EGFR immunoexpression was found 9.7% in well differentiated, 64.5% moderately differentiated and 25.8% in poorly differentiated tumours. Increased EGFR immunoexpression was observed predominantly in higher histological grades of ovarian cancers. Since, high EGFR levels have a negative prognostic role in ovarian cancers, further studies with long-term follow-ups are required to determine the prognosis and management of patients with malignant surface epithelial ovarian tumours.

Erlotinib in Advanced Well-Differentiated Thymic Carcinoma with Overexpression of EGFR: A Case Report

2008 ◽  
Vol 94 (6) ◽  
pp. 849-852 ◽  
Author(s):  
Rebecca Pedersini ◽  
Emanuela Vattemi ◽  
Maria Rita Lusso ◽  
Guido Mazzoleni ◽  
Heinrich Ebner ◽  
...  
Keyword(s):  
Thymic Carcinoma ◽  
Growth Factor Receptor ◽  
Ideal Solution ◽  
Egfr Expression ◽  
Therapeutic Choice ◽  
Heavily Pretreated ◽  
Epidermal Growth ◽  
Well Differentiated ◽  
Erlotinib Therapy ◽  
The Ideal

Aims and Background Advanced chemorefractory epithelial thymic tumors are still a challenge in clinical oncology. A therapeutic approach targeting a key molecular pathway could be the ideal solution in a neoplasm that can overexpress epidermal growth factor receptor (EGFR) in the epithelial component. Methods A patient with metastatic heavily pretreated thymic carcinoma was evaluated for EGFR expression in the primary tumor. Results Strong EGFR expression was revealed by immunohistochemistry. The patient received erlotinib therapy but had obtained no response after four months of treatment. Conclusion This preliminary experience suggests that erlotinib may not be a useful therapeutic choice in advanced pretreated thymic carcinomas.

scholarly journals Bi-Functional Radiotheranostics of 188Re-Liposome-Fcy-hEGF for Radio- and Chemo-Therapy of EGFR-Overexpressing Cancer Cells

2021 ◽  
Vol 22 (4) ◽  
pp. 1902 ◽  
Author(s):  
Yi-Shu Huang ◽  
Wei-Chuan Hsu ◽  
Chien-Hong Lin ◽  
Sheng-Nan Lo ◽  
Chu-Nian Cheng ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Cancer Cells ◽  
Tumor Cells ◽  
Cytotoxic Effect ◽  
Cytosine Deaminase ◽  
Growth Factor Receptor ◽  
Size Exclusion ◽  
Specific Therapy ◽  
Egfr Expression ◽  
Epidermal Growth

Epidermal growth factor receptor (EGFR) specific therapeutics is of great importance in cancer treatment. Fcy-hEGF fusion protein, composed of yeast cytosine deaminase (Fcy) and human EGF (hEGF), is capable of binding to EGFR and enzymatically convert 5-fluorocytosine (5-FC) to 1000-fold toxic 5-fluorocuracil (5-FU), thereby inhibiting the growth of EGFR-expressing tumor cells. To develop EGFR-specific therapy, 188Re-liposome-Fcy-hEGF was constructed by insertion of Fcy-hEGF fusion protein onto the surface of liposomes encapsulating of 188Re. Western blotting, MALDI-TOF, column size exclusion and flow cytometry were used to confirm the conjugation and bio-activity of 188Re-liposome-Fcy-hEGF. Cell lines with EGFR expression were subjected to treat with 188Re-liposome-Fcy-hEGF/5-FC in the presence of 5-FC. The 188Re-liposome-Fcy-hEGF/5-FC revealed a better cytotoxic effect for cancer cells than the treatment of liposome-Fcy-hEGF/5-FC or 188Re-liposome-Fcy-hEGF alone. The therapeutics has radio- and chemo-toxicity simultaneously and specifically target to EGFR-expression tumor cells, thereby achieving synergistic anticancer activity.

scholarly journals Epidermal growth factor receptor protein expression in lung cancer and survival analysis

2018 ◽  
Vol 5 (3) ◽  
pp. 550
Author(s):  
Shivalingaswamy Salimath ◽  
Jayaraj B. S. ◽  
Mahesh P. A. ◽  
M. D. Majeed Pasha ◽  
Lokesh K. S. ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Multivariate Analysis ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Performance Status ◽  
Growth Factor Receptor ◽  
Egfr Expression ◽  
Epidermal Growth ◽  
Nsclc Patients

Background: Epidermal Growth Factor Receptor (EGFR) is one of the important molecules involved in lung cancer initiation and progression. Studies on over expression of EGFR and its survival in relation with Non-small cell lung cancer (NSCLC) patients have yielded controversial results. Prevalence of EGFR expression in NSCLC patients and 6-month survival in south Indian population is unknown.Methods: We carried out a prospective study in tertiary hospital. Diagnosed patients with NSCLC were included in the study and were interviewed with questionnaire containing demography and investigations like Chest X-ray, CT thorax, Bronchoscopy were recorded. EGFR expression analysis was done for all patients and were followed up monthly for 6 months and details of survival and treatment were collected. Cox regression analysis was used to assess their survival.Results: 50 patients with NSCLC were included. Forty-four (88%) were men, median age of study group was 65 years. Twenty-seven patients (54%) had Adenocarcinoma, 14 patients (28%) had Squamous cell carcinoma, 7 patients (14%) had poorly differentiated carcinoma and 2 patients (4%) had large cell carcinoma. Thirty-four (68%) samples were positive for EGFR expression. On multivariate analysis we found patients who took chemotherapy and with good performance status (Karnofsky score >65 and Eastern Cooperative Oncology Group >2.5) had better survival at 6 months.Conclusions: Patients with EGFR positivity had better survival with chemotherapy but worse with radiotherapy. Patients who took chemotherapy and had good performance status had better survival on multivariate analysis. We didn’t find any correlation between EGFR positivity and poor survival.

scholarly journals Inhibition of epidermal growth factor receptor (EGFR) expression by human cytomegalovirus correlates with an increase in the expression and binding of Wilms' Tumour 1 protein to the EGFR promoter

2009 ◽  
Vol 90 (7) ◽  
pp. 1569-1574 ◽  
Author(s):  
Insiya Jafferji ◽  
Mark Bain ◽  
Christine King ◽  
John H. Sinclair
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Human Cytomegalovirus ◽  
Growth Factor Receptor ◽  
Cell Surface Receptor ◽  
Wilms Tumour ◽  
Promote Cell Proliferation ◽  
Egfr Expression ◽  
Epidermal Growth

Infection with human cytomegalovirus (HCMV) modulates the expression of a number of cellular receptors and is known to inhibit expression of the epidermal growth factor receptor (EGFR), a cell surface receptor that can promote cell proliferation through a cascade of intracellular signalling events. We have examined the mechanisms by which HCMV mediates downregulation of EGFR expression and show that virus infection results in the profound upregulation of Wilms' Tumour 1 (WT1) protein, a transcription factor associated with the negative regulation of a number of growth factors and growth factor receptors, including EGFR. Moreover, chromatin immunoprecipitation experiments also show that HCMV infection results in increased binding of WT1 to the EGFR promoter. Finally, we show that depleting the cell of WT1 using small interfering RNA abrogates virus-mediated downregulation of EGFR. Taken together, our observations suggest that HCMV-mediated repression of EGFR expression results from a virus-mediated increase in cellular WT1, a known pleiotropic regulator of mitogenesis, apoptosis and differentiation.

Sign in / Sign up

Export Citation Format

Share Document